Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Immunogen Inc.

Start price
Target price
Perf. (%)
€4.06
02.03.23
€14.17
02.03.24
612.84%
03.03.24

buy
Rhythm Pharmaceuticals

Start price
Target price
Perf. (%)
€23.20
02.03.23
€30.22
02.03.24
69.83%
03.03.24

3D Systems Corp.

Start price
Target price
Perf. (%)
€10.16
02.03.23
€6.61
02.03.24
-61.30%
03.03.24

Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€7.79
19.02.24
€6.00
16.05.26
-69.17%
03.03.24

Could be very worthwhile Investment >20% year
buy
Cytokinetics Inc.

Start price
Target price
Perf. (%)
€40.60
01.03.23
€54.33
01.03.24
63.79%
02.03.24

buy
Huron Consulting Group

Start price
Target price
Perf. (%)
€76.00
01.03.23
€88.97
01.03.24
21.05%
02.03.24

buy
Abercrombie + Fitch A

Start price
Target price
Perf. (%)
€26.44
01.03.23
€30.90
01.03.24
361.74%
02.03.24

Maxlinear Inc. A

Start price
Target price
Perf. (%)
€32.30
28.02.23
€28.34
28.02.24
-44.44%
29.02.24

buy
Barrett Business Services Inc.

Start price
Target price
Perf. (%)
€90.50
28.02.23
€96.12
28.02.24
16.02%
29.02.24

buy
Krystal Biotech

Start price
Target price
Perf. (%)
€77.50
28.02.23
€95.04
28.02.24
93.55%
29.02.24

buy
Cymabay Therapeutics Inc

Start price
Target price
Perf. (%)
€15.70
12.11.23
€20.00
31.03.26
89.81%
17.02.24

Could be very worthwhile Investment >20% year
buy
Kura Oncology Inc

Start price
Target price
Perf. (%)
€17.70
25.01.24
€16.00
31.08.25
9.60%
02.02.24

Could be very worthwhile Investment >20% year
buy
Marathon Digital Holdings

Start price
Target price
Perf. (%)
€5.33
12.01.23
€10.00
12.01.24
214.82%
13.01.24

Could be worthwhile Investment >10% per year
Novavax Inc.

Start price
Target price
Perf. (%)
€11.01
11.01.23
€6.00
11.01.24
-61.64%
12.01.24

Very low/no dividend yield expected
very negative Cash Flow expected
ROE lower than 10% per year
high free float
buy
Marathon Digital Holdings

Start price
Target price
Perf. (%)
€10.28
26.11.23
€14.00
26.11.24
42.61%
11.12.23

High dividend yield expected
Small Risks for its business
High valuation
Little Investments for future growth
buy
Marathon Digital Holdings

Start price
Target price
Perf. (%)
€10.38
28.11.23
€15.00
28.11.24
41.23%
09.12.23

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
Some uniques
Risky balance sheet
buy
MicroVision Inc

Start price
Target price
Perf. (%)
€2.44
02.12.23
€2.00
02.12.24
-1.29%
05.12.23

Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
buy
MicroVision Inc

Start price
Target price
Perf. (%)
€2.36
29.11.23
€2.00
29.11.24
3.49%
02.12.23

Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
buy
MicroVision Inc

Start price
Target price
Perf. (%)
€2.23
23.11.23
€2.00
23.11.24
5.92%
29.11.23

Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
buy
Sportsmans Wareh.ho.

Start price
Target price
Perf. (%)
€4.28
01.10.23
€4.50
30.09.25
11.68%
16.10.23

Could be very worthwhile Investment >20% year
buy
Blue Apron Holdings Inc.

Start price
Target price
Perf. (%)
€5.60
18.09.23
€11.40
18.09.24
116.07%
05.10.23

Could be very worthwhile Investment >20% year
Tupperware Brands Corp.

Start price
Target price
Perf. (%)
€1.57
19.09.23
€2.00
19.09.24
-8.03%
27.09.23

Risky Investment
RiceBran Technologies

Start price
Target price
Perf. (%)
€2.38
13.09.22
€1.00
13.09.23
-79.79%
14.09.23

Bed Bath & Beyond Inc.

Start price
Target price
Perf. (%)
€12.60
31.08.22
€10.00
31.08.23
-99.43%
01.09.23

Probably not worthwhile Investment
AMC Entertainment Holdings Inc.

Start price
Target price
Perf. (%)
€9.82
25.08.22
€8.00
25.08.23
-81.68%
26.08.23

Risky Investment
Increased challenges to pay loans and raise capital
Revenue decline/stagnation expected
Bad rating